Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants

NCT07372703 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-05-04

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV913 Capsules in healthy adults.

Conditions

  • Healthy Volunteers

Interventions

DRUG

VV913 1mg group

6 participants will receive VV913 1mg orally; 2 participants will receive placebo orally.

DRUG

VV913 2mg group

6 participants will receive VV913 2mg orally; 2 participants will receive placebo orally.

DRUG

VV913 4mg group

6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.

DRUG

VV913 8mg group

6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.

DRUG

VV913 15mg group

6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.

DRUG

VV913 25mg group

6 participants will receive VV913 25mg orally; 2 participants will receive placebo orally.

DRUG

VV913 40mg group

6 participants will receive VV913 40mg orally; 2 participants will receive placebo orally.

Sponsors & Collaborators

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Huan Zhou · The First Affiliated Hospital of Anhui Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-29
Primary Completion
2026-09-30
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07372703 on ClinicalTrials.gov